Researchers published new mechanistic evidence for CLN8, a protein whose mutations cause Batten disease, showing it functions as a stereospecific acyltransferase involved in bis(monoacylglycero)phosphate lipid biosynthesis. The findings, reported in Nature Cell Biology, address a long-standing mystery around how CLN8 defects derail lysosomal lipid handling. By pinpointing CLN8’s enzymatic role, the studies narrow the causal pathway between genotype and lysosomal lipid imbalance—an essential step toward targeted therapeutics for Batten disease and related neurodegenerative disorders. For drug developers, the work provides a clearer set of molecular targets and biomarkers tied to lipid recycling dysfunction.